Endometrial carcinomas in women aged 40 years and younger: Tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset

American Journal of Surgical Pathology

Volumn 33, Issue 12, 2009, Pages 1869-1877

  Garg, Karuna ^a   Shih, Karin ^b   Barakat, Richard ^b   Zhou, Qin ^a   Iasonos, Alexia ^a   Soslow, Robert A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Gynecology Service

Author keywords

Endometrial carcinoma; HNPCC Lynch syndrome; Young patients

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; G T MISMATCH BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PMS2 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADENOCARCINOMA; ADULT; AGE; ARTICLE; BIOPSY; CANCER STAGING; DOWN REGULATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MISMATCH REPAIR; MORTALITY; MULTIPLE CANCER; OVARY TUMOR; PATHOLOGY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA, CLEAR CELL; ADENOSINE TRIPHOSPHATASES; ADULT; AGE FACTORS; BIOPSY; CARCINOMA, ENDOMETRIOID; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTS HOMOLOG 2 PROTEIN; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73349097564     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181bc9866     Document Type: Article

References (59)

1. Benraad TJ, Friberg LG, Koenders AJ, et al. Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy? Acta Obstet Gynecol Scand. 1980;59:155-159.
2. Berends MJW, Wu Y, Sijmons RH, et al. Towards new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol. 2003;21:4364-4370.
3. Bewtra C, Watson P, Conway T, et al. Hereditary ovarian cancer: a clinicopathologic study. Int J Gynecol Pathol. 1992;11:180-188.
4. Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC. Cancer. 2006; 106:87-94.
5. Buttin BM, Powell MA, Mutch DG, et al. Increased risk for hereditary non-polyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res. 2004;10:481-490.
6. Cai KQ, Albarracin C, Rosen D, et al. Microsatellite instability and alteration of the expression of MLH1 and MSH2 in ovarian clear cell carcinoma. Hum Pathol. 2004;35:552-559.
7. Chiva L, Lapuente F, Gonzalez-Cortijo L, et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol. 2008; 111:S101-S104.
8. Colafranceschi M, Taddei GL, Scarselli G, et al. Clinico-pathologic profile of endometrial carcinoma in young women (under 40y of age). Eur J Gynecol Oncol. 1989;10:353-356.
9. Crissman JD, Azoury RS, Barnes AE, et al. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol. 1981;57: 699-704.
10. Duska LR, Garrett A, Rueda BR, et al. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83:388-393.
11. FIGO Announcements, stages-1988 revision. Gynecol Oncol. 1989; 35:125.
12. Fiumicino S, Ercoli A, Ferrandina G, et al. Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma. J Clin Oncol. 2001;19:1008-1014.
13. Furlan D, Carnevali I, Marcomini B, et al. The high frequency of denovo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res. 2006;12:3329-3336.
14. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984; 64:417-420.
15. Garg K, Leitao M, Kauff N, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohisto-chemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009;33:925-933.
16. Gehrig PA, Van Le L, Olatidoye B, et al. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer. 1999;86: 2083-2089.
17. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (Hereditary Non Polyposis Colorectal Cancer) among endometrial carcinoma patients. Cancer Res. 2006;66:7810-7817.
18. Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary non polyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004; 127:334-338.
19. Hoekstra AV, Kim JJ, Keh P, et al. Absence of progesterone receptors in a failed case of fertility sparing treatment in early endometrial cancer: a case report. J Reprod Med. 2008;53:869-873.
20. Ingram SS, Rosenman J, Heath R, et al. The predictive value of progesterone receptor levels in endometrial cancer. Int J Radiat Oncol Biol Phys. 1989;17:21-27.
21. Jensen KC, Mariappan MR, Putcha GV, et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age or younger. Am J Surg Pathol. 2008;32;1029-1032;1037.
22. Jeon YT, Park IA, Kim YB, et al. Steroid receptor expressions in endometrial cancer: clinical significance and epidemiologic implication. Cancer Letters. 2006;239:198-204.
23. Jongen V, Briet J, de Jong R, et al. Expression of estrogen receptor alpha and beta and progesterone receptor A and B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 2009;112:537-542.
24. Jung An H, Kim KI, Kim JY, et al. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol. 2007;31:846-853.
25. LaChance JA, Everett EN, Greer B, et al. The effect of age on clinical/pathologic features, surgical morbidity and outcome in patients with endometrial cancer. Gynecol Oncol. 2006;101:470-475.
26. Lu K, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007;25:5158-5164.
27. Martin PM, Rolland PH, Gammerre M, et al. Estradiol and progesterone receptors in normal and neoplastic endometrium: correlations between receptors, histopathological examinations and clinical responses under progestin therapy. Int J Cancer. 1979;23:321-329.
28. Matthews KS, Estes JM, Conner MG, et al. Lynch syndrome in women less than 50 years of age with endometrial cancer. Obst Gynecol. 2008;111:1161-1166.
29. McCourt CK, Mutch DG, Gibb RK, et al. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol. 2007;104:535-539.
30. Natarnicola M, Gristina R, Messa C, et al. Estrogen receptors and microsatellite instability in colorectal carcinoma patients. Cancer Lett. 2001;168:65-70.
31. Niwa K, Tagami K, Lian Z, et al. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG. 2005;112:317-320.
32. Ota T, Yoshida M, Kimura M, et al. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer. 2005;15:657-662.
33. Remmele W, Stegner HE. Recommendations for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138-140.
34. Rubatt JM, Slomovitz BM, Burke TW, et al. Development of metastatic endometrioid adenocarcinoma while on progesterone therapy for endometrial hyperplasia. Gynecol Oncol. 2005;99: 472-476.
35. Schmeler KM, Soliman PT, Sun CC, et al. Endometrial cancer in young, normal-weight women. Gynecol Oncol. 2005;99:388-392.
36. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology, Third series, fascicle 23, Published by the Armed Forces Institute of Pathology, 1998.
37. Shabani N, Kuhn C, Kunze S, et al. Prognostic significance of estrogen receptor alpha and beta, progesterone receptor A and B in endometrial carcinomas. Eur J Cancer. 2007;43:2434-2444.
38. Shamshirsaz AA, Withiam-Leitch M, Odunsi K, et al. Young patients with endometrial carcinoma selected for conservative treatment: a need for vigilance for synchronous ovarian carcinomas, case report and literature review. Gynecol Oncol. 2007;104:757-760.
39. Shannon C, Kirk J, Barnetson R, et al. Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium. Clin Cancer Res. 2003;9:1387-1392.
40. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for HNPCC. J Mol Diagn. 2008;10:293-300.
41. Shia JS, Black DB, Hummer AJ, et al. Routinely assessed morphologic features correlate with microsatellite instability status in endometrial cancer. Hum Pathol. 2008;39:116-125.
42. Silva EG, Deavers MT, Bodurka DC, et al. Association of low grade endometrioid carcinoma of the uterus and ovary with undiffer-entiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol. 2006;25:52-58.
43. Slattery ML, Potter JD, Curtin K, et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability positive colon cancer. Cancer Res. 2001;61:126-130.
44. Soliman PT, Slomovitz BM, Broaddus RR, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004;94:456-462.
45. Soliman PT, Broaddus RR, Schmeler KM, et al. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol. 2005;23:9344-9350.
46. Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105:575-580.
47. Thigpen T, Vance R, Lambuth B, et al. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer. 1987;60(8 suppl): 2104-2116.
48. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogester-one acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the gynecology oncology group. J Clin Oncol. 1999;17:1736-1744.
49. Uharcek P, Mlyncek M, Ravinger J, et al. Prognostic factors in women 45 years of age or younger with endometrial cancer. Int J Gynecol Cancer. 2008;18:324-328.
50. van den Bos M, van den Hoven M, Jongejan E, et al. More differences between HNPCC-related and sporadic carcinomas from the endometrium as compared to the colon. Am J Surg Pathol. 2004;28:706-711.
51. Wagner A, Hendriks Y, Meijers-Heijboer EJ, et al. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large dutch pedigree. J Med Genet. 2001;38:318-322.
52. Walsh MD, Cummings MC, Buchanan DD, et al. Molecular, pathologic and clinical features of early-onset endometrial cancer: identifying presumptive lynch syndrome patients. Clin Cancer Res. 2008;14:1692-1700.
53. Walsh C, Holschneider C, Hoang Y, et al. Coexisting ovarian malignancy in young women with endometrial cancer. Obst Gynecol. 2005;106:693-699.
54. Watson P, Butzow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2001;82:223-228.
55. Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: a newly described association with lynch syndrome. J Clin Oncol. 2008;26:5965-5971.
56. Whelan AJ, Babb S, Mutch DG, et al. MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. Int J Cancer. 2002; 99:697-704.
57. Yamagami W, Susumu N, Banno K, et al. Clinicopathologic manifestations of early onset endometrial cancer in Japanese women with a familial predisposition to cancer. J Obstet Gynecol Res. 2005;31:444-451.
58. Yamazawa K, Seki K, Matsui H, et al. Prognostic factors in young women with endometrial carcinoma: a report of 20 cases and review of the literature. Int J Gynecol Cancer. 2001;10:212-222.
59. Yamazawa K, Hirari M, Fujito A, et al. Fertility-preserving treatment with progestin and pathologic criteria to predict responses, in young women with endometrial cancer. Hum Repro. 2007;22:1953-1958.